tiprankstipranks
Argent Biopharma (RGTLF)
OTHER OTC:RGTLF

Argent Biopharma (RGTLF) Stock Price & Analysis

28 Followers

RGTLF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range<$0.01 - $1.40
Previous Close$0.5
Volume30.00
Average Volume (3M)593.00
Market Cap
$9.69M
Enterprise Value$9.50M
Total Cash (Recent Filing)AU$239.82K
Total Debt (Recent Filing)AU$575.14K
Price to Earnings (P/E)
Beta-1.68
Aug 28, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding43,851,631
10 Day Avg. Volume3
30 Day Avg. Volume593
Standard Deviation66.04
R-Squared0.04
Alpha5.53
Financial Highlights & Ratios
Price to Book (P/B)-139.36
Price to Sales (P/S)3.07
Price to Cash Flow (P/CF)-23.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

RGTLF FAQ

What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was <$0.01 and its highest was $1.40 in the past 12 months.
    What is Argent Biopharma’s market cap?
    Currently, no data Available
    When is Argent Biopharma’s upcoming earnings report date?
    Argent Biopharma’s upcoming earnings report date is Aug 28, 2024 which is in 36 days.
      How were Argent Biopharma’s earnings last quarter?
      Argent Biopharma released its earnings results on Feb 29, 2024. The company reported -$20.483 earnings per share for the quarter, missing the consensus estimate of N/A by -$20.483.
        Is Argent Biopharma overvalued?
        According to Wall Street analysts Argent Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Argent Biopharma pay dividends?
          Argent Biopharma does not currently pay dividends.
          What is Argent Biopharma’s EPS estimate?
          Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Argent Biopharma have?
          Argent Biopharma has 48,405,600 shares outstanding.
            What happened to Argent Biopharma’s price movement after its last earnings report?
            Argent Biopharma reported an EPS of -$20.483 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.538%.
              Which hedge fund is a major shareholder of Argent Biopharma?
              Currently, no hedge funds are holding shares in RGTLF
              ---

              Argent Biopharma Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Fundamentals

              Return on Equity
              Trailing 12-Months
              Asset Growth
              14.42%
              Trailing 12-Months

              Company Description

              Argent Biopharma

              MGC Pharmaceuticals Ltd is a European-based specialist Medical Cannabis company, in Phytocannabinoid-based medicine within the biopharmaceutical industry. The company's principal business goal is to produces and supply quality Cannabinoid based pharmaceutical products for the emergent medical markets in Europe, North America and Australasia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Arrowhead Pharmaceuticals
              Agios Pharma
              Alnylam Pharma
              Amarin
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis